Shares of Frequency Therapeutics (NASDAQ: FREQ) were crashing 74.9% as of 11:07 a.m. EDT on Tuesday. The huge drop came after the company announced disappointing top-line interim results from a phase ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate ...

Frequency Therapeutics (NASDAQ:FREQ) stock is rocketing higher on Friday following news that it will combine with Korro Bio. This merger plan is designed to bring Korro Bio public and will focus on ...

LEXINGTON, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate ...

Under the merger agreement's terms, stockholders of Korro Bio will receive newly issued shares of Frequency Therapeutics. Frequency Therapeutics has discontinued developing its remyelination program ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate ...

Frequency Therapeutics press release (NASDAQ:FREQ): Q4 GAAP EPS of -$0.49 beats by $0.14. As of December 31, 2022, Frequency had cash, cash equivalents and marketable securities of $83.1 million ...

The various current clinical trials for FX-322 are examining it as a treatment for different causes of hearing loss. The phase 2a trial focused mainly on two populations: noise-induced sensorineural ...

Frequency Therapeutics Inc. FREQ stock imploded Tuesday amid the company's announcement that its interim FX-322 Phase 2a results showed that four weekly injections did not demonstrate improvements in ...

Frequency Therapeutics Inc. (NASDAQ: FREQ) shares were absolutely crushed in Tuesday’s session. The catalyst for the 78% tumble was interim data from its hearing loss study. Although the initial move ...